Observing How Tildrakizumab Affects Quality of Life in Adults with Moderate-to-Severe Psoriasis in Canada

What this Trial Is About

Researchers are conducting a multi-centre, open-label, prospective observational study across Canada to evaluate the real-world impact, safety, and effectiveness of tildrakizumab in patients with moderate-to-severe plaque psoriasis. The study focuses on patients with Fitzpatrick skin types III and above, aiming to address the limited documentation of tildrakizumabs effects in Canadas diverse population. The findings will help improve care and ensure treatment outcomes reflect this populations needs. Participants will be patients initiating tildrakizumab as part of their routine care through the ILUMYA SUPPORT Program. The study will last 52 weeks, during which all enrolled patients will be observed without receiving additional interventions from the study team. The decision to start tildrakizumab treatment must occur independently before joining the study. During the study, participants will attend visits where researchers will assess quality of life using the Dermatology Life Quality Index DLQI, monitor psoriasis severity through measures like PASI, Body Surface Area, and Physician Global Assessment, and evaluate treatment impact on sleep, discomfort, and skin pain. Safety and adherence will be tracked throughout the 52-week period. The primary outcome focuses on DLQI changes at 16 weeks, with extended assessments continuing to week 52.

Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada